Century Therapeutics, Inc. Common Stock

IPSCNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
2.32 USD
↗ 0.02 (0.87%)AT CLOSE (11:59 AM EDT)
2.38
↗ 0.06 (2.76%)
POST MARKET (AS OF 06:54 PM EDT)
Post Market
AS OF 06:54 PM EDT
2.38
↗ 0.06 (2.76%)
🔴Market: CLOSED

IPSC is currently priced at $2.32. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 26, 2026.

Open?$2.28
High?$2.50
Low?$2.27
Prev. Close?$2.30
Volume?17.0M
Avg. Volume?1.5M
VWAP?$2.39
Rel. Volume?11.47x
Bid / Ask
Bid?$2.17 × 300
Ask?$2.51 × 200
Spread?$0.34
Midpoint?$2.34
Valuation & Ratios
Market Cap?418.4M
Shares Out?180.4M
Float?72.2M
Float %?40.2%
P/E Ratio?N/A
P/B Ratio?1.58
EPS?-$0.60
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Cell & Gene Therapy for Cancer
Employees
78
Market Cap
414.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.centurytx.com
Listed
2021-06-18
Address
25 N 38TH STREET, 11TH FLOOR
PHILADELPHIA, PA 19104
Phone: 215-981-4000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
2
Momentum?
50
Short Sent.?
9
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.13Distress
Confidence?57%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?21.34%Squeeze Risk
Short Interest?15.4M
Days to Cover?15.8
Free Float72.2M
Avg Daily Volume975.9K
Settlement Date2026-06-15
Financial Health
Current Ratio?10.25Strong
Quick Ratio?10.25Strong
Cash Ratio?3.76Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
85
1.58CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.9CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-40.7%WEAK▾
ROA?
S&P
3
-33.0%WEAK▾
Cash Flow & Enterprise
FCF?$-95472000
Enterprise Value?$367.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist